Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment

Kazuhiko Koizumi, Nobuyuki Enomoto, Masayuki Kurosaki, Takeshi Murakami, Namiki Izumi, Fumiaki Marumo, Chifumi Sato – 1 July 1995 – Hepatitis C virus (HCV) populations in vivo exist as a mixture of heterogeneous viruses called quasispecies, which have variations in the hypervariable region (HVR). However, the relationship between the diversity of HVR quasispecies, the disease stage, or the interferon (IFN) responsiveness remains to be elucidated.

A comparison of the surgical results in patients with hepatitis B versus hepatitis C‐related hepatocellular carcinoma

Kenji Takenaka, Kazuharu Yamamoto, Akinobu Taketomi, Hidetoshi Itasaka, Eisuke Adachi, Ken Shirabe, Takashi Nishizaki, Katsuhiko Yanaga, Keizo Sugimachi – 1 July 1995 – To assess the differences in the surgical results between patients with hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma (HCC), the operative outcomes of 30 patients with hepatitis B surface antigen (HBsAg)‐positive (the B‐HCC group) and 96 patients with hepatitis C antibody (HCVAb)‐positive (the C‐HCC group), who had undergone hepatic resection from 1989 to 1993, were compared.

Pathogenic role of hepatitis B virus in hepatitis B surface antigen—negative decompensated cirrhosis

Hau‐Tim Chung, Ching‐Lung Lai, Anna S. F. Lok – 1 July 1995 – This study was conducted to determine the rate of detection of serum hepatitis B virus (HBV) DNA in hepatitis B surface antigen (HBsAg)‐negative decompensated cirrhotic patients who had hepatitis B core and/or surface antibodies (anti‐HBc and/or anti‐HBs), and to compare the outcome of HBsAg‐positive cirrhotic patients who did or did not clear HBsAg during follow‐up. Six (5%) of 121 HBsAg‐positive cirrhotic patients lost HBsAg after 0.2 to 17.1 years (mean, 9.1 ± 6.2 yr) of follow‐up.

Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e–minus hepatitis B virus mutants

Hanns F. Löhr, Wolfgang Weber, Jörg Schlaak, Bernd Goergen, Karl‐Hermann Meyer Zum Büschenfelde, Guido Gerken – 1 July 1995 – To assess the significance of cell‐mediated immunity, T cells were derived from the peripheral blood and liver tissue of hepatitis B virus (HBV)‐infected patients and controls.

Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis

Kris V. Kowdley, Tarek Hassanein, Sumanjit Kaur, Frank J. Farrell, David H. van Thiel, Emmet B. Keeffe, Michael F. Sorrell, Bruce R. Bacon, Frederick L. Weber, Anthony S. Tavill – 1 July 1995 – Cirrhotic patients with hereditary hemochromatosis (HHC) have an increased risk of primary liver cancer (PLC). The purpose of this study was to determine the prevalence of primary liver cancer in patients with HHC undergoing orthotopic liver transplantation (OLT).

Subscribe to